Ascites Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Ascites pipeline constitutes 10+ key companies continuously working towards developing 10+ Ascites treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Ascites Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

"Ascites Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Ascites Market.

Some of the key takeaways from the Ascites Pipeline Report: https://www.delveinsight.com/sample-request/ascites-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Ascites treatment therapies with a considerable amount of success over the years.
• Ascites companies working in the treatment market are Wuhan YZY Biopharma Co., Ltd., Healthgen Biotechnology Corp., Grifols Therapeutics LLC, Versantis AG, Yale University, Noorik Biopharmaceuticals AG, and others, are developing therapies for the Ascites treatment
• Emerging Ascites therapies in the different phases of clinical trials are- M701, OrsHSA, Albutein 20% Injectable Solution, VS-01 on top of SOC, Empagliflozin 10 MG, Ambrisentan, and others are expected to have a significant impact on the Ascites market in the coming years.
• In May 2025, The phase III PRECIOSA trial demonstrated that long-term human albumin therapy did not significantly enhance survival in cirrhotic patients with acute decompensation and ascites. Treatment with human albumin (Albutein 20% solution) alongside standard medical care failed to achieve the primary endpoint of transplant-free survival (time to liver transplant or death within one year) compared to standard therapy alone (HR 0.80, 95% CI 0.58-1.11, P=0.17), according to Javier Fernández, MD, PhD, from Hospital Clínic de Barcelona.
• In January 2025, Sequana Medical NV has received US FDA approval for its Alfapump system to treat recurrent or refractory ascites caused by liver cirrhosis. This approval makes Alfapump the first active implantable device for this condition in the US.
• In November 2024, Martin Pharmaceuticals, a clinical-stage company focused on treating complications associated with advanced liver disease, has announced that findings from its DREAM study will be shared at the 75th Annual Liver Meeting, organized by the American Association for the Study of Liver Diseases (AASLD), taking place in San Diego, California, from November 15 to 19, 2024. Additionally, the company revealed that a crucial U.S. patent has been granted, providing protection for the use of its oral docarpamine therapy, CIQUAAX, in the treatment of ascites.

Ascites Overview
Ascites is the abnormal buildup of fluid in the abdomen, often caused by liver disease, cancer, or heart failure. It leads to swelling, discomfort, and difficulty breathing. Treatment focuses on addressing the underlying cause and removing excess fluid.

Get a Free Sample PDF Report to know more about Ascites Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/ascites-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Ascites Drugs Under Different Phases of Clinical Development Include:
• M701: Wuhan YZY Biopharma Co., Ltd.
• OrsHSA: Healthgen Biotechnology Corp.
• Albutein 20% Injectable Solution: Grifols Therapeutics LLC
• VS-01 on top of SOC: Versantis AG
• Empagliflozin 10 MG: Yale University
• Ambrisentan: Noorik Biopharmaceuticals AG

Ascites Route of Administration
Ascites pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Ascites Molecule Type
Ascites Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Ascites Pipeline Therapeutics Assessment
• Ascites Assessment by Product Type
• Ascites By Stage and Product Type
• Ascites Assessment by Route of Administration
• Ascites By Stage and Route of Administration
• Ascites Assessment by Molecule Type
• Ascites by Stage and Molecule Type

DelveInsight's Ascites Report covers around 5+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Ascites product details are provided in the report. Download the Ascites pipeline report to learn more about the emerging Ascites therapies
https://www.delveinsight.com/sample-request/ascites-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Ascites Therapeutics Market include:
Key companies developing therapies for Ascites are - Lindis Biotech, Wuhan Yzy Biopharma Co., Ltd., Clover Biopharmaceuticals, Binhui Biopharmaceutical, Pharmacyte Biotech Inc., And Others.

Ascites Pipeline Analysis:
The Ascites pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Ascites with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Ascites Treatment.
• Ascites key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Ascites Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Ascites market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Ascites drugs and therapies
https://www.delveinsight.com/sample-request/ascites-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Ascites Pipeline Market Drivers
• Increasing Prevalence of Liver Diseases, Advancements in Diagnostic Technologies, Innovative Ascites Treatment Approaches, Growing Research and Development, Rising Awareness and Screening Programs, are some of the important factors that are fueling the Ascites Market.

Ascites Pipeline Market Barriers
• However, High Ascites Treatment Costs, Limited Ascites Therapeutic Options, Side Effects and Complications, Regulatory Challenges, Limited Awareness in Low-Income Regions, and other factors are creating obstacles in the Ascites Market growth.

Scope of Ascites Pipeline Drug Insight
• Coverage: Global
• Key Ascites Companies: Wuhan YZY Biopharma Co., Ltd., Healthgen Biotechnology Corp., Grifols Therapeutics LLC, Versantis AG, Yale University, Noorik Biopharmaceuticals AG, and others
• Key Ascites Therapies: M701, OrsHSA, Albutein 20% Injectable Solution, VS-01 on top of SOC, Empagliflozin 10 MG, Ambrisentan, and others
• Ascites Therapeutic Assessment: Ascites current marketed and Ascites emerging therapies
• Ascites Market Dynamics: Ascites market drivers and Ascites market barriers

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.